Pilot Trial of Adaptive Radiotherapy Boost for HNSCC

Description

The purpose of the study is to determine if it is feasible to use magnetic resonance imaging (MRI) to adjust a portion of radiation therapy for patients with head and neck squamous cell carcinoma . The technique under study will be used to personalize the study treatment based on response, keeping all treatments within standard of care guidelines.

Conditions

Squamous Cell Carcinoma, Head and Neck Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of the study is to determine if it is feasible to use magnetic resonance imaging (MRI) to adjust a portion of radiation therapy for patients with head and neck squamous cell carcinoma . The technique under study will be used to personalize the study treatment based on response, keeping all treatments within standard of care guidelines.

Pilot Trial of Adaptive Radiotherapy Boost for Head and Neck Squamous Cell Carcinomas

Pilot Trial of Adaptive Radiotherapy Boost for HNSCC

Condition
Squamous Cell Carcinoma
Intervention / Treatment

-

Contacts and Locations

Tampa

Moffitt Cancer Center, Tampa, Florida, United States, 33612

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Provision of signed and dated informed consent form
  • * Stated willingness to comply with all study procedures and availability for the duration of the study
  • * ECOG performance status of 0, 1
  • * Patients with histologically or cytologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, or unknown primary in the neck.
  • * Patients with measurable disease, either at primary site or neck per RECIST 1.1.
  • * For patients planned to receive chemotherapy, adequate hematologic, hepatic and renal function as outlined in protocol.
  • * International normalized ratio of prothrombin time (INR) and prothrombin time (PT) within 28 days before randomization must be WNL for the lab. Patients who are therapeutically treated with an agent such as warfarin may participate if they are on a stable dose and no underlying abnormality in coagulation parameters exists per medical history.
  • * Negative serum pregnancy test within before starting study treatment in woman with childbearing potential.
  • * Pregnancy or lactation
  • * Patients who have had prior radiotherapy to the head and neck or prior systemic therapy for the index cancer.
  • * Patients who had undergone definitive surgery for the index cancer.
  • * Patients with distant metastatic disease
  • * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

H. Lee Moffitt Cancer Center and Research Institute,

George Yang, MD, PRINCIPAL_INVESTIGATOR, Moffitt Cancer Center

Study Record Dates

2026-10